natgillin/translations-raw huggingface dataset:
M2' and M3', the major metabolites in human faeces, were formed from M2 and lenvatinib, respectively, by aldehyde oxidase.
M2' in M3', poglavitna presnovka v človeškem blatu, sta nastala iz M2 oziroma lenvatiniba z aldehidno oksidazo.
The clinical efficacy and safety of lenvatinib have been evaluated in an international, multicenter, open-label, randomised phase 3 study (REFLECT) in patients with unresectable hepatocellular carcinoma (HCC).
Klinična učinkovitost in varnost lenvatiniba sta bili ocenjeni v mednarodni multicentrični odprti randomizirani študiji 3. faze (REFLECT) pri bolnikih z neoperabilnim hepatocelularnim karcinomom (HCC).
Therefore, the decision to resume lenvatinib following a major surgical procedure should be based on clinical judgment of adequate wound healing.
Odločitev za nadaljevanje zdravljenja z lenvatinibom po večjem kirurškem posegu mora zato temeljiti na klinični presoji, ali se rane primerno celijo.
Percentages (95% CI)
Odstotki (95-odstotni IZ)
Cases of fatal intracranial haemorrhage have been reported in some patients with or without brain metastases.
O primerih smrtnih znotrajlobanjskih krvavitev so poročali pri nekaterih bolnikih z zasevki v možganih ali brez njih.
• The active substance is lenvatinib.
• Učinkovina je lenvatinib.
• If you have severe liver or kidney problems the recommended dose is 14 mg once a day
• Če imate izrazite težave z jetri ali ledvicami, je priporočeni odmerek 14 mg enkrat na dan
PHARMACEUTICAL FORM AND CONTENTS 30 hard capsules 60 hard capsules 90 hard capsules METHOD AND ROUTE(S) OF ADMINISTRATION Oral use.
FARMACEVTSKA OBLIKA IN VSEBINA 30 trdih kapsul 60 trdih kapsul 90 trdih kapsul POSTOPEK IN POT(I) UPORABE ZDRAVILA Peroralna uporaba.
In addition, pneumothorax has been reported with and without clear evidence of a bronchopleural fistula.
Poleg tega so poročali o pnevmotoraksu, z jasnimi dokazi bronhoplevralne fistule in brez njih.
Details for monitoring, dose adjustment and discontinuation are provided in Table 2.
Podrobni podatki za spremljanje, prilagoditev odmerka in ukinitev zdravljenja so v preglednici 2.
Resolves to Grade 0-1.
Izboljša se na stopnjo 0-1
To dissolve them, pour a tablespoon of water or apple juice into a small glass and put the capsules into the liquid without breaking or crushing them.
Za raztapljanje nalijte jedilno žlico vode ali jabolčnega soka v majhen kozarec ter kapsule dodajte v tekočino, ne da bi jih prelomili ali zdrobili.
The median half-life was comparable in subjects with mild, moderate, and severe hepatic impairment as well as those with normal hepatic function and ranged from 26 hours to 31 hours.
Mediana razpolovna doba je bila primerljiva pri preiskovancih z blago, zmerno in hudo okvaro jeter, pa tudi pri tistih z normalno funkcijo jeter, in je bila v razponu od 26 ur do 31 ur.
• diarrhoea, feeling and being sick - these are very common side effects that can become serious if they cause you to become dehydrated, which can lead to kidney failure.
• driska, slabost in bruhanje - to so zelo pogosti neželeni učinki, ki lahko postanejo resni, če zaradi njih postanete dehidrirani, kar lahko povzroči odpoved ledvic.
• low levels of platelets in the blood which may lead to bruising and difficulty in wound healing
• nizka koncentracija krvnih ploščic v krvi, ki lahko povzroči modrice in oteženo celjenje ran.
Pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors, ATC code: L01XE29
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), inhibitorji proteinske kinaze, oznaka ATC: L01XE29.
• black, tarry, or bloody stools, or coughing up of blood - these may be signs of bleeding inside your body.
• črno, katranasto ali krvavo blato ali izkašljevanje krvi - to so lahko znaki krvavitve znotraj telesa;
Electrocardiograms should be monitored at baseline and periodically during treatment in all patients with particular attention to those with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, and those taking medicinal products known to prolong the QT interval, including Class Ia and III antiarrhythmics.
Elektrokardiograme je treba spremljati v izhodišču in v rednih presledkih ves čas zdravljenja pri vseh bolnikih, posebno pa moramo biti pozorni na tiste s prirojenim sindromom dolgega intervala QT, kongestivnim popuščanjem srca, z bradiaritmijami in pri tistih, ki jemljejo zdravila, za katera je znano, da podaljšujejo interval QT, vključno z antiaritmiki skupin Ia in III.
The degree of tumour invasion/infiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe haemorrhage associated with tumour shrinkage/necrosis following lenvatinib therapy.
Treba je oceniti stopnjo tumorske invazije/infiltracije večjih krvnih žil (npr. karotidnih arterij) zaradi možnega tveganja resne krvavitve, povezane z zmanjšanjem tumorske mase/nekrozo tumorja po zdravljenju z lenvatinibom.
• are a woman able to become pregnant (see the section below on Contraception, pregnancy and breast-feeding)
• ste ženska, ki bi lahko zanosila (glejte poglavje Kontracepcija, nosečnost in dojenje v nadaljevanju);
• The recommended dose of LENVIMA is usually 24 mg once a day
• Priporočeni odmerek zdravila LENVIMA je navadno 24 mg enkrat na dan
Caregivers should not open the capsule, in order to avoid repeated exposure to the contents of the capsule.
Skrbniki bolnikov naj ne odpirajo kapsul, da se bodo izognili večkratnemu izpostavljanju vsebini kapsul.
People get LENVIMA when their liver cancer has spread or cannot be taken out by surgery.
Bolniki prejmejo zdravilo LENVIMA, če se je rak jeter razširil ali ga s kirurškim posegom ni mogoče odstraniti.
Drink the mixture.
Suspenzijo spijte.
Leave for at least 10 minutes then stir for at least 3 minutes to dissolve the capsule shells.
Pustite jih v tekočini vsaj 10 minut, nato mešajte vsaj 3 minute, da se ovojnica kapsule raztopi.
What you need to know before you take LENVIMA
Kaj morate vedeti, preden boste vzeli zdravilo LENVIMA
It is not known whether lenvatinib is excreted in human milk.
Ni znano, ali se lenvatinib izloča v materino mleko.
Do not take LENVIMA if:
Ne jemljite zdravila LENVIMA:
In patients with solid tumours administered single and multiple doses of lenvatinib once daily, exposure to lenvatinib (Cmax and AUC) increased in direct proportion to the administered dose over the range of 3.2 to 32 mg once-daily.
Pri bolnikih s čvrstimi tumorji, ki so prejeli enkratne in večkratne odmerke lenvatiniba enkrat na dan, se je izpostavljenost lenvatinibu (Cmax in AUC) zvečala neposredno sorazmerno danemu odmerku v območju od 3,2 do 32 mg enkrat na dan.
Estimated using the Kaplan-Meier method; the 95% CI was constructed with a generalised Brookmeyer and Crowley method in patients with a best overall response of complete response or partial response.
Ocenjeno s Kaplan-Meierjevo metodo; 95-odstotni IZ je bil sestavljen s posplošeno Brookmeyer-Crowleyevo metodo pri bolnikih z najboljšim celotnim odzivom v obliki popolnega odziva ali delnega odziva.
The median time to onset was 26 days.
Mediani čas do nastopa je bil 26 dni.
Hypertension includes: hypertension, hypertensive crisis, increased diastolic blood pressure , , orthostatic hypertension, and increased blood pressure.
Hipertenzija vključuje: hipertenzijo, hipertenzivno krizo, zvišanje diastoličnega krvnega tlaka, ortostatsko hipertenzijo in zvišanje krvnega tlaka.
Table 4 Recommended management of hypertension
Preglednica 4 Priporočila za zdravljenje hipertenzije
Mild to moderate adverse reactions (e.g., Grade 1 or 2) generally do not warrant interruption of lenvatinib, unless intolerable to the patient despite optimal management.
Blagi do zmerni neželeni učinki (npr. stopnje 1 ali 2) na splošno ne upravičijo prekinitve odmerjanja lenvatiniba, razen če jih bolnik ne more prenašati kljub optimalni obravnavi.
There was no statistically significant difference in overall survival between the treatment groups at the time of the primary efficacy analysis (HR=0.73; 95% CI: 0.50, 1.07, p=0.1032).
Ni bilo statistično značilne razlike v celotnem preživetju med skupinama z različnima zdravljenjema v času analize primarne učinkovitosti (HR (hazard ratio; razmerje tveganja)=0,73; 95 % IZ: 0,50; 1,07, p=0,1032).
Radioiodine-refractory was defined as one or more measurable lesions either with a lack of iodine uptake or with progression in spite of radioactive-iodine (RAI) therapy, or having a cumulative activity of RAI of >600 mCi or 22 GBq with the last dose at least 6 months prior to study entry.
Odpornost proti radioaktivnemu jodu je bila opredeljena kot ena ali več merljivih lezij bodisi brez privzema joda bodisi z napredovanjem bolezni kljub zdravljenju z radioaktivnim jodom (RAI) ali s kumulativno aktivnostjo RAI > 600 mCi ali 22 GBq z zadnjim odmerkom vsaj 6 mesecev pred vključitvijo v študijo.
Men had a higher incidence (26.5%) of dysphonia than women (12.3%), decreased weight and decreased platelet count.
Moški pa so imeli večje incidenco (26,5 %) hripavosti kot ženske (12,3 %), hujšanja in zmanjšanja števila trombocitov.
Similar adverse reactions were observed in clinical trials in DTC and HCC.
Neželeni učinki, ugotovljeni v kliničnih preskušanjih pri DTC in HCC, so bili podobni.
BP should be monitored after 1 week of treatment with lenvatinib, then every 2 weeks for the first 2 months, and monthly thereafter.
KT je treba spremljati po 1 tednu zdravljenja z lenvatinibom, nato prva 2 meseca vsaka 2 tedna in zatem enkrat na mesec.
• feeling very tired or weak
• močna utrujenost ali šibkost,
When systolic BP ≤150 mmHg, diastolic BP ≤95 mmHg, and patient has been on a stable dose of antihypertensive therapy for at least 48 hours, resume lenvatinib at a reduced dose (see section 4.2)
Ko je sistolični KT ≤ 150 mmHg, diastolični KT ≤ 95 mmHg, bolnik pa je že vsaj 48 ur na stabilnem odmerku antihipertenzivne terapije, spet začnite dajati lenvatinib v zmanjšanem odmerku (glejte poglavje 4.2).
m: Hepatocellular damage and hepatitis includes: drug-induced liver injury, hepatic steatosis, and cholestatic liver injury.
m: Hepatocelularna poškodba in hepatitis vključujeta: z zdravili povzročeno poškodbo jeter, steatozo jeter in holestatično poškodbo jeter.
Reversibility of the toxicologic changes was observed at the end of a 4-week recovery period in all animal species investigated.
Pri vseh raziskovanih živalskih vrstah so opazili reverzibilnost toksikoloških sprememb ob koncu 4-tedenskega obdobja okrevanja.
Hypocalcaemia (see section 4.4, QT interval prolongation)
Hipokalciemija (glejte poglavje 4.4 Podaljšanje intervala QT)
The Rac in HCC subjects with mild and moderate liver impairment was similar to that reported for other solid tumours.
Vrednost Rac pri bolnikih s HCC z blago in zmerno okvaro jeter je bila podobna vrednosti, ki je bila opisan pri drugih čvrstih tumorjih.
Not adjusted for crossover effect.
Brez popravka za učinek prehoda.
CI, confidence interval; NE, not estimable; OS, overall survival; PFS, progression-free survival; RPSFT, rank preserving structural failure time model; VEGF/VEGFR, vascular endothelial growth factor / vascular endothelial growth factor receptor.
IZ, interval zaupanja; NE, ni bilo mogoče oceniti; OS, celotno preživetje; PFS, preživetje brez napredovanja bolezni; RPSFT, model ohranjanja ranga strukturnih napak glede na čas; VEGF/VEGFR, rastni faktor vaskularnega endotelija/receptor za rastni faktor vaskularnega endotelija.
Blood Pressure (BP) level
Raven krvnega tlaka (KT)
Stratified by region (Region 1: Asia-Pacific; Region 2: Western), macroscopic portal vein invasion or extrahepatic spread or both (yes, no), ECOG PS (0, 1) and body weight (<60 kg, ≥60 kg).
b Stratificirano po regijah (regija 1: Azija-Pacifik; regija 2: zahodna), makroskopski invaziji portalne vene ali razširjenosti izven jeter ali oboje (da, ne), ECOG PS (0, 1) in telesni masi
• drowsiness, confusion, poor concentration, loss of consciousness that may be signs of liver failure
• utrujenost, zmedenost, slaba koncentracija, izguba zavesti, ki so lahko znaki težav jetrne odpovedi,
There was a higher incidence of decreased neutrophil count in patients with HCC (8.7% on lenvatinib than in other nonHCC tumour types (1.4%)), which was not associated with infection, sepsis or bacterial peritonitis.
Pri bolnikih s HCC je bila večja pojavnost zmanjšanega števila nevtrofilcev (8,7 % pri lenvatinibu v primerjavi z drugimi tipi tumorjev brez HCC (1,4 %)), ki ni bila povezana z okužbo, sepso ali bakterijskim peritonitisom.
If you are not sure talk to your doctor before taking LENVIMA.
Če ste negotovi, se posvetujte z zdravnikom, preden začnete jemati zdravilo LENVIMA.
However, in vivo data indicated that non-P450-mediated pathways contributed to a significant portion of the overall metabolism of lenvatinib.
Vendar so podatki in vivo pokazali, da so presnovne poti, ki ne potekajo preko citokroma P450, prispevale k pomembnemu deležu celotne presnove lenvatiniba.
Because it is not known if LENVIMA can reduce the effect of the oral contraceptive pill, if this is your normal method of contraception you should ensure you also add a barrier method such as the cap or condoms if you have sex during treatment with LENVIMA.
Ker ni znano, ali zdravilo LENVIMA lahko zmanjša učinek peroralnih kontracepcijskih tablet, morate v primeru, če je to vaša normalna metoda kontracepcije, zagotoviti, da boste dodatno uporabljali še eno od pregradnih metod kontracepcije, npr. diafragmo ali kondome, če med zdravljenjem z zdravilom LENVIMA spolno občujete.
Lenvatinib is not a substrate for OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K or the bile salt export pump BSEP.
Lenvatinib ni substrat za OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K ali izločevalno črpalko žolčnih soli BSEP.
Following independent review confirmation of disease progression, 109 (83.2%) patients randomised to placebo had crossed over to open-label lenvatinib at the time of the primary efficacy analysis.
Po potrditvi napredovanja bolezni z neodvisnim pregledom je 109 bolnikov (83,2 %), randomiziranih na placebo, v času primarne analize učinkovitosti prešlo na odprti lenvatinib.
• yellow skin or yellowing of the whites of the eyes (jaundice) or drowsiness, confusion, poor concentration - these may be signs of liver problems.
• rumena koža ali porumenelost beločnic (zlatenica) ali zaspanost, zmedenost, slaba koncentracija - to so lahko znaki težav z jetri;
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.
Lenvatinib je inhibitor receptorjev tirozin-kinaze (RTK), ki selektivno inhibira kinazne aktivnosti receptorjev rastnega faktorja vaskularnega endotelija (vascular endothelial growth factor ali VEGF) VEGFR1 (FLT1), VEGFR2 (KDR) in VEGFR3 (FLT4), poleg drugih RTK, povezanih z drugimi proangiogenimi in onkogenimi potmi, vključno z receptorji za fibroblastni rastni faktor (fibroblast growth factor ali FGF) FGFR1, 2, 3 in 4, receptorjem za rastni faktor iz trombocitov (platelet derived growth factor ali PDGF) PDGFRα, KIT in RET.
Lenvatinib should not be started in patients with fistula to avoid worsening and lenvatinib should be permanently discontinued in patients with oesophageal or tracheobronchial tract involvement and any Grade 4 fistula (see section 4.2); limited information is available on the use of dose interruption or reduction in management of other events, but worsening was observed in some cases and caution should be taken.
Lenvatiniba ne smemo začeti dajati bolnikom s fistulo, da se izognemo poslabšanju, trajno pa ga moramo ukiniti pri bolnikih s prizadetostjo ezofagealnega ali traheobronhialnega trakta in kakršno koli fistulo stopnje 4 (glejte poglavje 4.2); o uporabi prekinitve ali zmanjšanja odmerjanja za zdravljenje drugih dogodkov je na voljo malo podatkov, vendar so v nekaterih primerih opazili poslabšanje, zato je potrebna previdnost.
No adjustment of starting dose is required on the basis of age.
Na podlagi starosti prilagoditev začetnega odmerka ni potrebna.
Patients were excluded who had prior systemic anticancer therapy for advanced/unresectable HCC or any prior anti-VEGF therapy.
Bolniki so bili izključeni, če so imeli predhodno sistemsko terapijo proti raku za napredovali/neoperabilni HCC ali katero koli predhodno zdravljenje z zdravili, usmerjenimi proti VEGF.
Following administration of radiolabelled lenvatinib to 6 patients with solid tumours, approximately two-thirds and one-quarter of the radiolabel were eliminated in the faeces and urine, respectively.
Po dajanju radioaktivno označenega lenvatiniba 6 bolnikom s čvrstimi tumorji se je približno dve tretjini oziroma ena četrtina radioaktivnega označevalca odstranila iz telesa z blatom oziroma urinom.
LENVIMA may cause side effects that can affect your ability to drive or use machines.
Zdravilo LENVIMA lahko povzroči neželene učinke, ki lahko vplivajo na vašo sposobnost upravljanja vozil ali strojev.
Posterior reversible encephalopathy syndrome Monoparesis Transient ischaemic attack
sindrom posteriorne reverzibilne encefalopatije monopareza tranzitorna ishemična ataka
Data from a human mass balance/excretion study indicate lenvatinib is extensively metabolised in humans.
Podatki iz študije masnega ravnovesja/izločanja pri ljudeh kažejo, da se lenvatinib pri ljudeh intenzivno presnavlja.
The objective response rate (complete response [CR] plus partial response [PR]) per independent radiological review was significantly (p<0.0001) higher in the lenvatinib-treated group (64.8%) than in the placebo-treated group (1.5%).
Objektivna odzivnost (popolni odziv [CR] plus delni odziv [PR]) po neodvisnem radiološkem pregledu je bila značilno (p < 0,0001) večja v skupini, zdravljeni z lenvatinibom (64,8 %), kot v skupini, ki je prejemala placebo (1,5 %).
In this trial, there was 1 case of fatal intracranial haemorrhage among 16 patients who received lenvatinib and had CNS metastases at baseline.
V tem preskušanju je bil 1 primer smrtne znotrajlobanjske krvavitve med 16 bolniki, ki so prejemali lenvatinib in so v izhodišču imeli zasevke v centralnem živčevju.
Based on a population pharmacokinetic analysis of patients receiving up to 24 mg lenvatinib once daily, age, sex, weight, and race (Japanese vs. other, Caucasian vs. other) had no significant effects on clearance (see section 4.2).
Na podlagi populacijske farmakokinetične analize bolnikov, ki so prejemali do 24 mg lenvatiniba enkrat na dan, starost, spol, telesna masa in rasa (Japonci v primerjavi z drugimi, belci v primerjavi z drugimi) niso značilno vplivali na očistek (glejte poglavje 4.2).
Liver function tests should be monitored before initiation of treatment, then every 2 weeks for the first 2 months and monthly thereafter during treatment.
Teste funkcije jeter je treba spremljati pred začetkom zdravljenja, med zdravljenjem pa prva 2 meseca vsaka 2 tedna in nato enkrat na mesec.
LENVIMA is a medicine that contains the active substance lenvatinib.
LENVIMA je zdravilo, ki vsebuje zdravilno učinkovino lenvatinib.
Most reactions resolved following supportive treatment, without dose interruption or reduction, which occurred in 1.5% and 1.1% of patients, respectively; 1 patient with Grade 4 hypocalcaemia discontinued treatment permanently.
Večina neželenih učinkov je po podpornem zdravljenju izginila brez prekinitve ali zmanjšanja odmerka, do katerih je prišlo pri 1,5 % oziroma 1,1 % bolnikov; pri enem bolniku s hipokalciemijo stopnje 4 so zdravljenje trajno ukinili.
Carcinogenicity studies have not been conducted with lenvatinib.
Študij kancerogenosti za lenvatinib niso opravili.
The results for surrogate endpoints (PFS and ORR) are presented in Table 7 below.
Rezultati za nadomestne opazovane dogodke (PFS in objektivno odzivnost) so predstavljeni v preglednici 7 v nadaljevanju.
Dose adjustments and discontinuations for DTC
Prilagajanje odmerka in ukinitev pri DTC
Pharmacokinetic parameters of lenvatinib have been studied in healthy adult subjects, adult subjects with hepatic impairment, renal impairment, and solid tumours.
Farmakokinetične parametre lenvatiniba so proučevali pri zdravih odraslih preiskovancih, odraslih preiskovancih z okvaro jeter, okvaro ledvic in čvrstimi tumorji.
• dry, sore, or inflamed mouth, odd taste sensation
• suha, boleča ali vneta usta, občutek čudnega okusa,
Patients with hypertension
Bolniki s hipertenzijo
• If it is less than 12 hours until your next dose: skip the missed dose.
• Če do naslednjega odmerka manjka manj kot 12 ur: pozabljeni odmerek izpustite.
• dry skin, thickening and itching of the skin
• suha koža, zadebelitev in srbenje kože,
The median OS had not been reached for either the lenvatinib group or the placebo crossover group.
Mediano OS ni bilo doseženo niti pri skupini z lenvatinibom niti pri skupini, ki je s placeba prešla na lenvatinib.
Hepatic encephalopathy tended to be associated with adverse disease characteristics at baseline or with the use of concomitant medications.
Jetrna encefalopatija je bila večinoma povezana z neugodnimi značilnostmi bolezni v izhodišču ali s sočasno uporabo zdravil.
What LENVIMA is and what it is used for What you need to know before you take LENVIMA How to take LENVIMA
Kaj je zdravilo LENVIMA in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo LENVIMA Kako jemati zdravilo LENVIMA Možni neželeni učinki
The toxicity of lenvatinib was more prominent in younger rats (dosing initiated on PND7) compared with those with dosing initiated on PND21 and mortality and some toxicities were observed earlier in the juvenile rats at 10 mg/kg compared with adult rats administered the same dose level.
Toksičnost lenvatiniba je bila izrazitejša pri mlajših podganah (odmerjanje se je začelo na PND7) kot pri tistih, pri katerih se je odmerjanje začelo na PND21, in so smrtnost in nekatere toksičnosti prej opazili pri mladih podganah pri odmerku 10 mg/kg v primerjavi z odraslimi podganami, ki so prejemale enako raven odmerkov.
Other medicines and LENVIMA
Druga zdravila in zdravilo LENVIMA
In vitro, cytochrome P450 3A4 was demonstrated as the predominant (>80%) isoform involved in the P450-mediated metabolism of lenvatinib.
In vitro so pokazali, da je citokrom P450 3A4 prevladujoča (> 80 %) izooblika vpletena v presnovo lenvatiniba, ki poteka preko P450.
Lenvatinib has not been studied in patients who have had an arterial thromboembolism within the previous 6 months, and therefore should be used with caution in such patients.
Pri bolnikih, ki so imeli v predhodnih 6 mesecih arterijsko trombembolijo, lenvatiniba niso proučevali, zato ga je treba pri takih bolnikih previdno uporabljati.
Gastrointestinal toxicity should be actively managed in order to reduce the risk of development of renal impairment or renal failure.
Toksičnost za prebavila je treba aktivno obvladovati, da se zmanjša tveganje nastanka okvare ledvic ali odpovedi ledvic.
P-value d
Vrednost pd
• If you become pregnant while being treated with LENVIMA, tell your doctor immediately.
• Če med zdravljenjem z zdravilom LENVIMA zanosite, to takoj povejte zdravniku.
PRES is a neurological disorder which can present with headache, seizure, lethargy, confusion, altered mental function, blindness, and other visual or neurological disturbances.
PRES je nevrološka bolezen, ki se lahko kaže z glavobolom, epileptičnim napadom, letargijo, zmedenostjo, spremenjenim duševnim stanjem, slepoto in drugimi motnjami vida ali nevrološkimi motnjami.
The capsules must be left in the liquid for at least 10 minutes and stirred for at least 3 minutes to dissolve the capsule shells.
Kapsule pustimo v tekočini vsaj 10 minut in mešamo vsaj 3 minute, da se ovojnica kapsule raztopi.
Kaplan-Meier Curve of Progression-Free Survival - DTC
Slika 1 Kaplan-Meierjeva krivulja preživetja brez napredovanja bolezni - DTC